An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Teladoc Health has partnered with Eli Lilly's LillyDirect and pharmacy provider GiftHealth to expand access to Zepbound, a GLP-1 drug prescribed for weight loss. The partnership allows Teladoc ...

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

Eligible Teladoc Health members, if prescribed Zepbound ® by their Teladoc Health provider for an on-label indication, can have single-use Zepbound ® vials delivered directly to their home. Teladoc ...